115 related articles for article (PubMed ID: 25331982)
1. DNA methylome profiling beyond promoters - taking an epigenetic snapshot of the breast tumor microenvironment.
Jeschke J; Collignon E; Fuks F
FEBS J; 2015 May; 282(9):1801-14. PubMed ID: 25331982
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation in the tumor microenvironment.
Zhang MW; Fujiwara K; Che X; Zheng S; Zheng L
J Zhejiang Univ Sci B; 2017 May; 18(5):365-372. PubMed ID: 28471108
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.
Trnkova L; Buocikova V; Mego M; Cumova A; Burikova M; Bohac M; Miklikova S; Cihova M; Smolkova B
Biomed Pharmacother; 2024 May; 174():116559. PubMed ID: 38603889
[TBL] [Abstract][Full Text] [Related]
4. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1.
Zeng H; Irwin ML; Lu L; Risch H; Mayne S; Mu L; Deng Q; Scarampi L; Mitidieri M; Katsaros D; Yu H
Breast Cancer Res Treat; 2012 May; 133(1):127-35. PubMed ID: 21837478
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
6. Unravelling the epigenomic dimension of breast cancers.
Dedeurwaerder S; Fumagalli D; Fuks F
Curr Opin Oncol; 2011 Nov; 23(6):559-65. PubMed ID: 21946247
[TBL] [Abstract][Full Text] [Related]
7. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
[TBL] [Abstract][Full Text] [Related]
8. Distinct epigenetic changes in the stromal cells of breast cancers.
Hu M; Yao J; Cai L; Bachman KE; van den Brûle F; Velculescu V; Polyak K
Nat Genet; 2005 Aug; 37(8):899-905. PubMed ID: 16007089
[TBL] [Abstract][Full Text] [Related]
9. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
10. Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells.
Putnik M; Zhao C; Gustafsson JÅ; Dahlman-Wright K
Biochem Biophys Res Commun; 2012 Sep; 426(1):26-32. PubMed ID: 22902638
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
12. The biological and clinical significance of stromal-epithelial interactions in breast cancer.
McCuaig R; Wu F; Dunn J; Rao S; Dahlstrom JE
Pathology; 2017 Feb; 49(2):133-140. PubMed ID: 28040198
[TBL] [Abstract][Full Text] [Related]
13. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation profiling reveals a predominant immune component in breast cancers.
Dedeurwaerder S; Desmedt C; Calonne E; Singhal SK; Haibe-Kains B; Defrance M; Michiels S; Volkmar M; Deplus R; Luciani J; Lallemand F; Larsimont D; Toussaint J; Haussy S; Rothé F; Rouas G; Metzger O; Majjaj S; Saini K; Putmans P; Hames G; van Baren N; Coulie PG; Piccart M; Sotiriou C; Fuks F
EMBO Mol Med; 2011 Dec; 3(12):726-41. PubMed ID: 21910250
[TBL] [Abstract][Full Text] [Related]
15. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.
Rody A; Holtrich U; Solbach C; Kourtis K; von Minckwitz G; Engels K; Kissler S; Gätje R; Karn T; Kaufmann M
Endocr Relat Cancer; 2005 Dec; 12(4):903-16. PubMed ID: 16322330
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic values of GHSR DNA methylation pattern in breast cancer.
Botla SK; Gholami AM; Malekpour M; Moskalev EA; Fallah M; Jandaghi P; Aghajani A; Bondar IS; Omranipour R; Malekpour F; Mohajeri A; Babadi AJ; Sahin Ö; Bubnov VV; Najmabadi H; Hoheisel JD; Riazalhosseini Y
Breast Cancer Res Treat; 2012 Oct; 135(3):705-13. PubMed ID: 22899222
[TBL] [Abstract][Full Text] [Related]
18. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
Hoque MO; Feng Q; Toure P; Dem A; Critchlow CW; Hawes SE; Wood T; Jeronimo C; Rosenbaum E; Stern J; Yu M; Trink B; Kiviat NB; Sidransky D
J Clin Oncol; 2006 Sep; 24(26):4262-9. PubMed ID: 16908936
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin.
Lee SE; Kim SJ; Yoon HJ; Yu SY; Yang H; Jeong SI; Hwang SY; Park CS; Park YS
J Pineal Res; 2013 Jan; 54(1):80-8. PubMed ID: 22856590
[TBL] [Abstract][Full Text] [Related]
20. [Epigenetic aspects of early lymphogenic metastasis in breast cancer].
Skriabin NA; Lebedev IN; Tolmachëva EN; Vtorushin SV; Slonimskaia EM; Cherbyntseva NV
Vopr Onkol; 2011; 57(6):717-21. PubMed ID: 22416386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
